In conclusion, this study showed that BSI is strongly associated with overall survival in patients with high-risk prostate cancer receiving primary hormonal therapy and that BSI includes prognostic information in addition to clinical T stage, Gleason score and PSA. This evidence concerns the gene KLK3 and prostate carcinoma.